<?xml version="1.0" encoding="UTF-8"?>
<p id="para0025">Evidence has accumulated to show that VLPs promote protective immunity against infectious diseases including flu, hand, foot, and mouth disease, hepatitis B, and HPV infection [
 <xref rid="bib0098" ref-type="bibr">98</xref>, 
 <xref rid="bib0102" ref-type="bibr">102</xref>, 
 <xref rid="bib0103" ref-type="bibr">103</xref>, 
 <xref rid="bib0104" ref-type="bibr">104</xref>, 
 <xref rid="bib0105" ref-type="bibr">105</xref>, 
 <xref rid="bib0106" ref-type="bibr">106</xref>]. The immunogenicity of HBV VLP was significantly higher than the recombinant protein vaccine. HBV VLP elicits neutralizing antibodies and is capable of stimulating specific CD8
 <sup>+</sup> and CD4
 <sup>+</sup> T cell responses 
 <italic>in vivo</italic>
 <xref rid="bib0107" ref-type="bibr">[107]</xref>. VLPs may also be used as a potential therapeutic vaccine owing to their powerful effect on the induction of antiviral immunity 
 <xref rid="bib0108" ref-type="bibr">[108]</xref>. Some VLP vaccines for HPV are already commercially available, including Cervarix®, Gardasil®, and Gardasil9®, and Sci-B-Vac™ is an HBV vaccine [
 <xref rid="bib0102" ref-type="bibr">102</xref>, 
 <xref rid="bib0105" ref-type="bibr">105</xref>, 
 <xref rid="bib0109" ref-type="bibr">109</xref>]. VLPs are generated in insect or yeast expression systems, which can express complex viral protein antigens on a large scale for commercial purposes 
 <xref rid="bib0110" ref-type="bibr">[110]</xref>.
</p>
